Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
about
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataInhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Antiviral drugs against hepatitis C virus.Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeuticsInhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodiesUse of illumina deep sequencing technology to differentiate hepatitis C virus variants.Current status and future directions in the management of chronic hepatitis C.Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirNaturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.Anti-HCV drugs in the pipeline.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitorSerine protease inhibitors as anti-hepatitis C virus agents.Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Boceprevir and personalized medicine in hepatitis C virus infectionComparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients.Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infectionProtease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.The presence of additional resistance-related polymorphisms to NS3 protease inhibitors in hepatitis C virus sequences from the Los Alamos databank.
P2860
Q27490545-7B73A653-E53D-4F53-862E-B27041743956Q31042796-73E4B6FC-4539-421A-B9B9-517FA8C7CD1AQ33798180-85C2AA3E-C260-4D51-B3C1-657EF868FF04Q34409020-5ADABA9A-9A44-43FB-931B-E2F697D18EC8Q35105567-A4485C7C-886A-4EB5-9036-E91D74DB7337Q35376259-6FC82076-E78C-4D51-ADAD-989175F3F62FQ35587088-E58409B2-18F8-449E-99FB-3968D24C5574Q35806939-F469BC4A-30C0-40F0-B930-087EDDF5AE9CQ35887719-CC3C2530-8D22-4BA3-9B2A-06802D53BB7BQ36276803-B5D2340B-9EE3-40FC-8AC3-A40BF8769436Q36384127-96C9B0E1-C0E9-41AB-9E77-F8B5F722D196Q37177740-DE933007-4BD6-4CEF-AB60-93D26A60727AQ37263558-C5E03C24-96CB-4185-9B15-549E086D8C95Q37503337-00294636-FA1F-4FF8-A142-025670517BF0Q37967467-74F1E2C7-893B-404A-A554-D824BF21A59AQ37990840-4E15E6C1-1CC8-4CBF-94C2-D6CC3786A6E3Q38066185-2524C7CB-E6D9-4388-9B43-20B09809727BQ38283239-704890F2-4323-43C3-9026-61183E6B1C90Q38699377-3642440F-A7F7-480F-8AC4-4A5E6D6FDC25Q39627463-1D2CAC80-8BD1-4693-BF1B-255CCF31EFDDQ41632962-E9ED259E-8675-43DB-8813-9C2C5CA46597Q42145002-A49297CD-F657-4F5C-9B4B-A918E798ED50Q42205040-9E613432-0BCA-49B1-99E1-81304389F8E9Q42991856-92734A8E-FE53-463B-89A7-0C2C4201AF6EQ42999029-E91F3022-4F10-407A-BAA3-A972A767B767
P2860
Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@ast
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@en
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@nl
type
label
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@ast
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@en
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@nl
prefLabel
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@ast
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@en
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@nl
P2093
P2860
P356
P1476
Selection and Characterization ...... 96 and Boceprevir (SCH 503034)
@en
P2093
Anita Y M Howe
Anne M Deatly
Colin Broom
Emilio A Emini
Lynn Z Miller
Mike Flint
Robert Ralston
Stanley Mullen
P2860
P304
P356
10.1128/AAC.01081-08
P407
P577
2009-02-01T00:00:00Z